Nocturia, nocturnal incontinence prevalence, and response to anticholinergic and behavioral therapy.
To determine whether participants in the behavior enhances drug reduction of incontinence (BE-DRI) trial experienced reduction in the frequency of nocturia and/or nocturnal leakage during treatment with antimuscarinic phamacotherapy with or without additional behavioral therapy. We analyzed urinary diary data relating to nocturia and nocturnal incontinence before and after 8 weeks of study treatment in the BE-DRI trial, in which patients were randomly assigned to receive drug therapy with tolterodine tartrate extended-release capsules 4 mg alone or in combination with behavioral training. Chi-square tests assessed whether nocturia and nocturnal incontinence prevalence varied by treatment arm and paired t tests assessed the change in mean frequency of nocturia and nocturnal leakage. Among 305 women, 210 (69%) had an average of at least one nocturia episode at baseline. There were small but statistically significant differences (p < 0.001) in mean nocturia frequency and nocturnal incontinence frequency with both treatments after 8 weeks, but no significant difference between study treatment groups. Among these urge incontinent women, tolterodine with or without supervised behavioral therapy had little impact on either nocturic frequency or nocturnal incontinence.
Fitzgerald
M P
MP
Loyola University Medical Center, Maywood, IL 60153, USA. Mfitzg8@lumc.edu
Lemack
G
G
Wheeler
T
T
Litman
H J
HJ
D000284:Administration, Oral; D001521:Behavior Therapy / Q000379:methods*; D001559:Benzhydryl Compounds / Q000008:administration & dosage*; D018680:Cholinergic Antagonists / Q000008:administration & dosage; D003408:Cresols / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D053158:Nocturia / Q000453:epidemiology* / Q000503:physiopathology / Q000628:therapy; D053206:Nocturnal Enuresis / Q000453:epidemiology* / Q000503:physiopathology / Q000628:therapy; D010665:Phenylpropanolamine / Q000008:administration & dosage*; D015995:Prevalence; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D014563:Urodynamics / Q000502:physiology
D001559:Benzhydryl Compounds; D018680:Cholinergic Antagonists; D003408:Cresols; D003692:Delayed-Action Preparations; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate